Oncotarget

Meta-Analysis:

Prognostic value of HPV DNA status in cervical cancer before treatment: a systematic review and meta-analysis

Ping Li, Yue Tan, Li-Xia Zhu, Li-Na Zhou, Ping Zeng, Qin Liu, Min-Bin Chen and Ye Tian _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:66352-66359. https://doi.org/10.18632/oncotarget.18558

Metrics: PDF 1870 views  |   HTML 2884 views  |   ?  


Abstract

Ping Li1,2,*, Yue Tan1,2,*, Li-Xia Zhu3,*, Li-Na Zhou1,2, Ping Zeng2, Qin Liu3, Min-Bin Chen2 and Ye Tian1

1Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, Institute of Radiotherapy and Oncology, Soochow University, Suzhou 215004, Jiangsu Province, China

2Department of Radiotherapy and Oncology, Kunshan First People’s Hospital Affiliated to Jiangsu University, Kunshan 215300, Jiangsu Province, China

3Department of Gynecology, Kunshan First People’s Hospital Affiliated to Jiangsu University, Kunshan 215300, Jiangsu Province, China

*These authors contributed equally to this work and share co-first authors

Correspondence to:

Ye Tian, email: [email protected]

Keywords: HPV, cervical cancer, prognosis, overall survival, disease free survival

Received: January 23, 2017     Accepted: May 19, 2017     Published: June 16, 2017

ABSTRACT

Background: Human papillomavirus (HPV), has been recognized as an vital preliminary event in the oncogenesis of cervical cancer. But the prognostic value is not well defined, because of past studies showing conflicting results. So we conducted this meta-analysis to evaluate whether HPV DNA status was associated with prognosis in cervical cancer.

Materials and Methods: A total of 17 previously published eligible studies including 2,838 cases were identified and included in this meta-analysis. Positive HPV DNA was associated with good prognosis in patients with cervical cancer (overall survival [OS]: pooled hazard ratio (HR) = 0.610, 95% confidence interval (CI) = 0.457−0.814, P = 0.001; disease free survival [DFS]: pooled HR = 0.362, 95% CI = 0.252−0.519, P < 0.001). Furthermore, in subgroup analysis, the results revealed that the association between HPV DNA positive cervical cancers and better OS (pooled HR = 0.534, 95 % CI = 0.355–0.804, P = 0.003) in Mongoloid patients. Similarly, it existed in good OS (pooled HR = 0.628, 95 % CI 0.429−0.922, P = 0.017) and DFS (pooled HR = 0.355, 95% CI = 0.226−0.559, P < 0.001) in Caucasian patients.

Conclusions: HPV DNA status in cervical cancer may be a useful prognostic biomarker before carcinomas are treated. However, larger sample sizes and more comprehensive studies are required in the future studies to verify our findings.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18558